Ruxolitinib

ASN007 (ERK-IN-3) is a potent and orally active inhibitor of ERK . ASN007 inhibits ERK1/2 with low single-digit nM IC 50 values. ASN007 can be used for the research of cancers driven by RAS mutationsIn VitroASN007 (ERK-IN-3) inhibits the

ASN007 (ERK-IN-3) is a potent and orally active inhibitor of ERK . ASN007 inhibits ERK1/2 with low single-digit nM IC 50 values. ASN007 can be used for the research of cancers driven by RAS mutationsIn VitroASN007 (ERK-IN-3) inhibits the

General description Diffuse gliomas are classified based on histological and molecular features to achieve an integrated diagnosis. Molecular diagnostic markers include IDH mutation, 1p/19q co-deletion, and TP53 mutation.

An antagonist of ER&alpha that blocks 17&beta-estradiol-induced proliferation of drug-resistant cancer cell lines at concentrations ranging from 10 to 1,000 nM drives tumor regression in mice bearing MCF-7 xenografts inhibits ER&alpha-dependent

An orally bioavailable inhibitor of MEK1/2 (IC₅₀ = 12 nM) that inhibits ERK phosphorylation in various cancer cell lines (IC₅₀s &ge 5 nM) efficacious in several xenograft tumor models in mice, including those bearing K-Ras or

A cell permeable inhibitor of PKC with IC₅₀ values reported to range from 0.10 to 0.

BOLD-100 (NKP-1339: IT-139) free base is a ruthenium-based anticancer agent. BOLD-100 free base also is an inhibitor of stress-induced GRP78 upregulation, disrupting endoplasmic reticulum (ER) homeostasis and inducing ER stress and unfolded protein

BOLD-100 (NKP-1339: IT-139) free base is a ruthenium-based anticancer agent. BOLD-100 free base also is an inhibitor of stress-induced GRP78 upregulation, disrupting endoplasmic reticulum (ER) homeostasis and inducing ER stress and unfolded protein

BOLD-100 (NKP-1339: IT-139) free base is a ruthenium-based anticancer agent. BOLD-100 free base also is an inhibitor of stress-induced GRP78 upregulation, disrupting endoplasmic reticulum (ER) homeostasis and inducing ER stress and unfolded protein

Biochem/physiol Actions BPK-29 is a potent and selective NR0B1 ligand that covalently binds to NR0B1 Cys 274. BPK-29 inhibits the NR0B1-SNW1 interaction.

Biochem/physiol Actions BPK-29 is a potent and selective NR0B1 ligand that covalently binds to NR0B1 Cys 274. BPK-29 inhibits the NR0B1-SNW1 interaction.

Bryostatin 2 is a macrocyclic lactone with anti-tumor properties and activator of PKC (protein kinase C) which inhibit the growth of A549 cells. Bryostatin 2 has been documented to compete with phorbol ester binding to PKC at a K|i|= 3.4 nM and